The Top Biopharma Pharma Stories of 2004
Executive Summary
Windhover's pick of the top pharma/ biotech stories of 2004 range from the firestorm over Vioxx and Celebrex, the problem of the blockbuster pharma model, the biogenerics that weren't, the pricing squeeze on drugs; greater scrutiny of clinical data from a beleaguered, gun-shy FDA; new uses of existing molecules, which "jump-started" companies looking for financing; the tail-end of Big Pharma consolidation; and the rise of oncology.